Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine

• Published in: British journal of cancer Vol. 126; no. 5; pp. 754 - 763
• Main Authors: Chen, Vincent, Umemura, Shigeki, Han, Yumin, Raman, Renuka, Tucker, Robin, Chahine, Joeffrey, Kim, In-Kyu, Schatz, Christoph, Zitzmann-Kolbe, Sabine, Sommer, Anette, Onda, Masanori, Lee, Trevor, He, Yongfeng, Giaccone, Giuseppe
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.03.2022; Nature Publishing Group
• Subjects: 631/67/1059/153; 692/4028; Animals; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Cisplatin; Cisplatin - administration & dosage; Cisplatin - pharmacology; Cytotoxicity; Drug delivery; Drug Resistance; Drug Synergism; Epidemiology; Female; Flow cytometry; Gene Expression Regulation, Neoplastic - drug effects; HT29 Cells; Humans; Immunoconjugates - administration & dosage; Immunoconjugates - pharmacology; Maytansine - administration & dosage; Maytansine - analogs & derivatives; Maytansine - pharmacology; Mesothelin - genetics; Mesothelin - metabolism; Mice; Molecular Medicine; Neoplasms, Glandular and Epithelial - drug therapy; Neoplasms, Glandular and Epithelial - genetics; Neoplasms, Glandular and Epithelial - metabolism; Oncology; Thymoma; Thymoma - drug therapy; Thymoma - genetics; Thymoma - metabolism; Thymus; Thymus Neoplasms - drug therapy; Thymus Neoplasms - genetics; Thymus Neoplasms - metabolism; Tumor cell lines; Tumors; Up-Regulation - drug effects; Xenograft Model Antitumor Assays; Xenografts

Background Thymic epithelial tumours (TETs) are rare tumours comprised of thymomas and thymic carcinoma. Novel therapies are needed, especially in thymic carcinoma where the 5-year survival rate hovers at 30%. Mesothelin (MSLN), a surface glycoprotein that is cleaved to produce mature MSLN (mMSLN) a...